Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430 · View on ClinicalTrials.gov ↗
Study Summary
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Conditions Studied
Interventions
- BIOLOGICAL GV20-0251
- BIOLOGICAL GV20-0251 and Pembrolizumab [KEYTRUDA®]
Study Locations (13)
Texas
- Oncology Consultants, P.A. — Houston
- The University of Texas M. D. Anderson Cancer Center — Houston
California
- The Angeles Clinic and Research Institute — Los Angeles
Colorado
- HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE — Denver
Connecticut
- Yale University — New Haven
Florida
- Florida Cancer Specialists & Research Institute, LLC — Fort Myers
Indiana
- Community Health Network, Inc. — Indianapolis
Massachusetts
- Massachusetts General Hospital — Boston
Michigan
- Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center — Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2023-03-23 |
| Est. Completion | 2027-09-05 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05669430
The ClinicalTrials.gov registry entry for NCT05669430 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GV20 Therapeutics, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions — of which GV20-0251 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05669430 reports 13 study locations spanning 12 distinct geographic areas — top geographies include Texas, California, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05669430 about?
NCT05669430 is a clinical study titled "A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies". This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
What is the current status of trial NCT05669430?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 365 participants. The study started on 2023-03-23. Estimated completion is 2027-09-05.
What conditions does trial NCT05669430 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Solid Tumor, Adult, Cutaneous Melanoma, Refractory Cancer, Endometrial Carcinoma (EC). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05669430?
The interventions under investigation include: GV20-0251 (BIOLOGICAL), GV20-0251 and Pembrolizumab [KEYTRUDA®] (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05669430?
This trial is sponsored by GV20 Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05669430 being conducted?
This trial has 13 study locations across California, Colorado, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.